Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.

Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X.

Carcinogenesis. 2013 May;34(5):1006-11. doi: 10.1093/carcin/bgt006. Epub 2013 Jan 14.

2.

Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer.

Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X.

Cancer Prev Res (Phila). 2010 Oct;3(10):1235-45. doi: 10.1158/1940-6207.CAPR-10-0035. Epub 2010 Sep 21.

3.

Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Ke HL, Lin J, Ye Y, Wu WJ, Lin HH, Wei H, Huang M, Chang DW, Dinney CP, Wu X.

Ann Surg Oncol. 2015 Nov;22(12):4104-10. doi: 10.1245/s10434-015-4431-5. Epub 2015 Apr 8.

PMID:
25851338
4.

Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer.

Lee EK, Ye Y, Kamat AM, Wu X.

Cancer. 2013 May 1;119(9):1643-51. doi: 10.1002/cncr.27871. Epub 2013 Mar 25.

5.

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin.

Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X.

PLoS One. 2012;7(6):e38533. doi: 10.1371/journal.pone.0038533. Epub 2012 Jun 12.

6.

Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer.

Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X.

Cancer Res. 2008 Apr 1;68(7):2530-7. doi: 10.1158/0008-5472.CAN-07-5991.

7.

Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response.

Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K.

Cancer Res. 2010 Dec 1;70(23):9765-76. doi: 10.1158/0008-5472.CAN-10-0130. Epub 2010 Nov 30.

8.

Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma.

Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X.

Carcinogenesis. 2010 Oct;31(10):1805-12. doi: 10.1093/carcin/bgq168. Epub 2010 Aug 23.

9.

Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.

Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.

Eur Urol. 2012 Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25.

PMID:
22101115
10.

Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.

Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X.

Clin Cancer Res. 2005 Feb 15;11(4):1408-15.

11.

Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.

Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X.

J Clin Oncol. 2005 Aug 20;23(24):5746-56.

12.

Genetic variants in miRNAs predict bladder cancer risk and recurrence.

Wang M, Chu H, Li P, Yuan L, Fu G, Ma L, Shi D, Zhong D, Tong N, Qin C, Yin C, Zhang Z.

Cancer Res. 2012 Dec 1;72(23):6173-82. doi: 10.1158/0008-5472.CAN-12-0688. Epub 2012 Jul 30.

13.

MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.

Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X.

Carcinogenesis. 2010 Dec;31(12):2118-23. doi: 10.1093/carcin/bgq177. Epub 2010 Sep 5.

14.

Prognostic relevance of urinary bladder cancer susceptibility loci.

Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, Vermeulen SH, Kiemeney LA.

PLoS One. 2014 Feb 25;9(2):e89164. doi: 10.1371/journal.pone.0089164. eCollection 2014.

15.

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD.

BJU Int. 2001 Aug;88(3):209-16. Review.

16.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

17.

Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival.

Sung H, Jeon S, Lee KM, Han S, Song M, Choi JY, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D.

BMC Cancer. 2012 May 28;12:195. doi: 10.1186/1471-2407-12-195.

18.

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M.

Cochrane Database Syst Rev. 2000;(4):CD001986. Review.

PMID:
11034738
19.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.

Yoon KA, Yoon H, Park S, Jang HJ, Zo JI, Lee HS, Lee JS.

J Thorac Cardiovasc Surg. 2012 Oct;144(4):794-807. doi: 10.1016/j.jtcvs.2012.06.030. Epub 2012 Jul 18.

PMID:
22818121
20.

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, Davis ID, Stockler MR.

BJU Int. 2013 May;111(6):977-83. doi: 10.1111/j.1464-410X.2012.11390.x. Epub 2012 Dec 17. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk